YGYu Geng

Yu Geng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yu Geng has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Fang-Hua Lee

    ProSci Incorporated, 12170 Flint Place, Poway, California 92064,1 Department of Microbiology, University of Pennsylvania, 225 Johnson Pavilion, Philadelphia, Pennsylvania 19104,2 Institute of Human Virology, Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, Maryland 212013

    2 shared publications
  • Hu Fu

    ProSci Incorporated, 12170 Flint Place, Poway, California 92064,1 Department of Microbiology, University of Pennsylvania, 225 Johnson Pavilion, Philadelphia, Pennsylvania 19104,2 Institute of Human Virology, Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, Maryland 212013

    2 shared publications
  • Innocent Mboudjeka

    ProSci Incorporated, 12170 Flint Place, Poway, California 92064,1 Department of Microbiology, University of Pennsylvania, 225 Johnson Pavilion, Philadelphia, Pennsylvania 19104,2 Institute of Human Virology, Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, Maryland 212013

    2 shared publications
  • Robert J. Luallen

    ProSci Inc., 12170 Flint Place, Poway, CA 92064, USA

    2 shared publications
  • Robert W. Doms

    ProSci Incorporated, 12170 Flint Place, Poway, California 92064,1 Department of Microbiology, University of Pennsylvania, 225 Johnson Pavilion, Philadelphia, Pennsylvania 19104,2 Institute of Human Virology, Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, Maryland 212013

    2 shared publications
  • Caroline Agrawal

    ProSci Incorporated, 12170 Flint Place, Poway, California 92064,1 Department of Microbiology, University of Pennsylvania, 225 Johnson Pavilion, Philadelphia, Pennsylvania 19104,2 Department of Surgery, Duke University Medical Center, Box 2926, DUMC, Durham, North Carolina 27710,3 Department of Biochemistry, Emory University School of Medicine, 1510 Clifton Rd. NE, Room 4035, Atlanta, Georgia 303224

    1 shared publication

Latest Publications

  • A Yeast Glycoprotein Shows High-Affinity Binding to the Broadly Neutralizing Human Immunodeficiency Virus Antibody 2G12 and Inhibits gp120 Interactions with 2G12 and DC-SIGN

    by Robert J. Luallen, Hu Fu, Caroline Agrawal-Gamse, Innocent Mboudjeka, Wei Huang, Fang-Hua Lee, Lai-Xi Wang, Robert W. Doms, Yu Geng

    The human immunodeficiency virus type 1 (HIV-1) envelope (Env) protein contains numerous N-linked carbohydrates that shield conserved peptide epitopes and promote trans infection by dendritic cells via binding to cell surface lectins. The potent and broadly neutralizing monoclonal antibody 2G12 binds a cluster of high-mannose-type oligosaccharides on the gp120 subunit of Env, revealing a conserved and highly exposed epitope on the glycan shield. To find an effective antigen for eliciting 2G12-like antibodies, we searched for endogenous yeast proteins that could bind to 2G12 in a panel of Saccharomyces cerevisiae glycosylation knockouts and discovered one protein that bound weakly in a Δ pmr1 strain deficient in hyperglycosylation. 2G12 binding to this protein, identified as Pst1, was enhanced by adding the Δ mnn1 deletion to the Δ pmr1 background, ensuring the exposure of terminal α1,2-linked mannose residues on the D1 and D3 arms of high-mannose glycans. However, optimum 2G12 antigenicity was found when Pst1, a heavily N-glycosylated protein, was expressed with homogenous Man 8 GlcNAc 2 structures in Δ och1 Δ mnn1 Δ mnn4 yeast. Surface plasmon resonance analysis of this form of Pst1 showed high affinity for 2G12, which translated into Pst1 efficiently inhibiting gp120 interactions with 2G12 and DC-SIGN and blocking 2G12-mediated neutralization of HIV-1 pseudoviruses. The high affinity of the yeast glycoprotein Pst1 for 2G12 highlights its potential as a novel antigen to induce 2G12-like antibodies.


  • An Engineered Saccharomyces cerevisiae Strain Binds the Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody 2G12 and Elicits Mannose-Specific gp120-Binding Antibodies

    by Robert J. Luallen, Jianqiao Lin, Hu Fu, Karen K. Cai, Caroline Agrawal, Innocent Mboudjeka, Fang-Hua Lee, David Montefiori, David F. Smith, Robert W. Doms, et al.

    The glycan shield of the human immunodeficiency virus type 1 (HIV-1) envelope (Env) protein serves as a barrier to antibody-mediated neutralization and plays a critical role in transmission and infection. One of the few broadly neutralizing HIV-1 antibodies, 2G12, binds to a carbohydrate epitope consisting of an array of high-mannose glycans exposed on the surface of the gp120 subunit of the Env protein. To produce proteins with exclusively high-mannose carbohydrates, we generated a mutant strain of Saccharomyces cerevisiae by deleting three genes in the N-glycosylation pathway, Och1, Mnn1 , and Mnn4 . Glycan profiling revealed that N-glycans produced by this mutant were almost exclusively Man 8 GlcNAc 2 , and four endogenous glycoproteins that were efficiently recognized by the 2G12 antibody were identified. These yeast proteins, like HIV-1 gp120, contain a large number and high density of N-linked glycans, with glycosidase digestion abrogating 2G12 cross-reactivity. Immunization of rabbits with whole Δ och1 Δ mnn1 Δ mnn4 yeast cells produced sera that recognized a broad range of HIV-1 and simian immunodeficiency virus (SIV) Env glycoproteins, despite no HIV/SIV-related proteins being used in the immunization procedure. Analyses of one of these sera on a glycan array showed strong binding to glycans with terminal Manα1,2Man residues, and binding to gp120 was abrogated by glycosidase removal of high-mannose glycans and terminal Manα1,2Man residues, similar to 2G12. Since S. cerevisiae is genetically pliable and can be grown easily and inexpensively, it will be possible to produce new immunogens that recapitulate the 2G12 epitope and may make the glycan shield of HIV Env a practical target for vaccine development.